Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galiximab + Rituximab in Relapsed/Refractory Follicular NHL
NCT00363636Phase 3Terminated
- Sponsor
- Biogen
- Start
- Sep 2006
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) comparing Galiximab + Rituximab with Rituximab + Placebo (2 arms). Primary endpoint: Progression-Free Survival at 4 years. Started Sep 2006; status: terminated.
02
Drugs
galiximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00363636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363636.